MarketPeel
Insider Trading Intelligence
Pricing
…
SC

Sohanya Roshan Cheng

KPTI
EVP & CHIEF COMMERCIAL OFFICER · KARYOPHARM THERAPEUTICS INC. · CIK 0001865796
FILING MIX · LIFETIME59%/41%
BUYS
17
SELLS
12
TOTAL VALUE
$162.0K
COMPANIES
1
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
107,940
AVG SELL PX
$2.57
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 7 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Sohanya Roshan Cheng, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+54.55%+3.51%+0.15%+3.36%-1.87%—
14d11+36.36%+1.85%+0.51%+1.34%-2.25%—
30d11+45.45%-0.88%+0.34%-1.22%-0.24%—
60d11+54.55%-1.20%+3.70%-4.90%-5.87%—
90d11+63.64%-14.47%+5.50%-20.90%-21.56%—
180d11(1 pending)+80.00%-19.27%+8.46%-27.73%-27.04%—
1y11(2 pending)+88.89%-42.43%+21.59%-64.01%-72.76%—
2y11(4 pending)+100.00%-69.35%+45.08%-114.43%-128.09%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KPTI · 107,940 shares · as of May 14, 2026
0105,115210,229315,344420,45820222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 12 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
324$9.50$3.1K107,940May 14, 2026May 15, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
947——108,264May 13, 2026May 15, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
4,604$9.41$43.3K107,317Mar 2, 2026Mar 3, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
32,415——111,921Jan 31, 2026Feb 3, 2026 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
43,650——79,506Oct 15, 2025Oct 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
325$6.43$2.1K35,856Sep 15, 2025Sep 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
945——36,181Sep 12, 2025Sep 16, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
3,445$6.29$21.7K34,314Mar 4, 2025Mar 6, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
9,166——9,166Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
10,833——10,833Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
4,583——37,759Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
5,416——33,176Feb 28, 2025Mar 4, 2025 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
5,356$0.72$3.9K404,051Sep 4, 2024Sep 5, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
5,109$1.20$6.1K393,509Mar 1, 2024Mar 4, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
21,840$1.17$25.6K398,618Feb 29, 2024Mar 4, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
198,959——420,458Feb 28, 2024Feb 29, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
14,167——221,499Jan 24, 2024Jan 25, 2024 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
7,415$1.33$9.9K204,086Sep 1, 2023Sep 5, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
1,839$2.35$4.3K211,501Jun 8, 2023Jun 12, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
EVP & Chief Commercial Officer
11,239$3.03$34.0K210,687Mar 1, 2023Mar 2, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
100,000——221,926Feb 28, 2023Mar 2, 2023 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
30,000——119,949Aug 31, 2022Sep 1, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
45,000——45,000Aug 31, 2022Sep 1, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
Chief Commercial Officer
66$5.35$35391,434Jun 13, 2022Jun 14, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
SALE
Chief Commercial Officer
1,485$5.20$7.7K89,949Jun 13, 2022Jun 14, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
84,000——91,500Feb 28, 2022Mar 2, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
108,000——108,000Feb 28, 2022Mar 2, 2022 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
7,500——7,500Jun 30, 2021Jul 1, 2021 ↗View →
KPTI
KARYOPHARM THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
125,000——125,000Jun 30, 2021Jul 1, 2021 ↗View →
Other insiders · KPTI
Loading peer insiders…
About this filer
CIK 0001865796
ROLE
EVP & Chief Commercial Officer
PRIMARY
KPTI
COMPANIES
1
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001865796DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback